FDA Using More Temporary Advisory Committee Members To Fill Vacancies
This article was originally published in The Tan Sheet
Executive Summary
FDA advisory committees are increasingly relying on temporary members to fill their ranks - a trend that could result in less predictability for drug sponsors at a make-or-break review meeting
You may also be interested in...
Meet The NDAC, Minus One, As Conflict Of Interest Rules Come Into Play
New Nonprescription Drugs Advisory Committee member James Kehrer's expertise on acetaminophen toxicity should make him a key figure at FDA's upcoming meeting on the drug, he says
Meet The NDAC, Minus One, As Conflict Of Interest Rules Come Into Play
New Nonprescription Drugs Advisory Committee member James Kehrer's expertise on acetaminophen toxicity should make him a key figure at FDA's upcoming meeting on the drug, he says
Meet The NDAC, Minus One, As Conflict Of Interest Rules Come Into Play
New Nonprescription Drugs Advisory Committee member James Kehrer's expertise on acetaminophen toxicity should make him a key figure at FDA's upcoming meeting on the drug, he says